![Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease - Roy A. Pleasants, 2019 Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease - Roy A. Pleasants, 2019](https://journals.sagepub.com/cms/10.1177/1060028018798753/asset/images/large/10.1177_1060028018798753-fig2.jpeg)
Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease - Roy A. Pleasants, 2019
![Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD | Business Wire Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD | Business Wire](https://mms.businesswire.com/media/20171205006502/en/628187/4/3135393_Lonhala_Magnair_Logo_25mcg_1mL.jpg)
Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD | Business Wire
![Sunovion Pharmaceuticals Inc. - Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD Sunovion Pharmaceuticals Inc. - Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD](https://s23.q4cdn.com/866595044/files/doc_events/2017/12/1/LM_NebulizerSystem.jpg)
Sunovion Pharmaceuticals Inc. - Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD
![Sunovion Pharmaceuticals Inc. - Sunovion Announces Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD Sunovion Pharmaceuticals Inc. - Sunovion Announces Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD](https://s23.q4cdn.com/866595044/files/doc_events/2018/04/1/svn_pos_clr_rgb.jpg)